[Elsevier/Sciencedirect] Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

 关闭 求助已关闭
Lily2001 发表于 2026-7-21 17:27:04 | 显示全部楼层 |阅读模式
悬赏20积分

期刊:Journal of Allergy and Clinical Immunology

文献作者:Stephan Weidinger; Andrew Blauvelt; Kim A. Papp; Adam Reich; Chih-Hung Lee; Margitta Worm; Charles Lynde; Yoko Kataoka; Peter Foley; Xiaodan Wei; Wanling Wong; Anne-Catherine Solente; Christine Weber; Samuel Adelman; Sonya Davey; Fabrice Hurbin; Natalie Rynkiewicz; Karl Yen; John T. O’Malley; Charlotte Bernigaud

出版日期:2025-4-

DOI号:10.1016/j.jaci.2024.10.031

下载链接:https://www.sciencedirect.com/sc ... 091674924011758/pdf

文献链接:https://doi.org/10.1016/j.jaci.2024.10.031

当前文献来源于 Elsevier BV


备注信息:
全部回复0 显示全部楼层

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

高级会员
  • 发布

  • 回复

  • 积分

    360

返回列表